SCHEMBL5146624

SCHEMBL5146624

O=C1NC(=O)C(=Cc2ccc(-c3ccc(C(=O)O)cc3)o2)C(=O)N1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.69
KMT2A Q03164 5/20 0.69
MITF O75030 1/20 0.69
SIRT2 Q8IXJ6 3/20 0.64
GSK3A P49840 1/20 0.64
GSK3B P49841 1/20 0.64
GFER P55789 2/20 0.63
G6PD P11413 2/20 0.63
INSR P06213 1/20 0.62
IGF1R P08069 1/20 0.62
CDK2 P24941 1/20 0.61
POLB P06746 2/20 0.61
DNMT1 P26358 1/20 0.61
CTDSP1 Q9GZU7 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
BRAF P15056 4/20 0.59
METAP1 P53582 1/20 0.58
KDM4E B2RXH2 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
DUSP3 P51452 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764803 0.90 SIRT2 (0.80) MEN1KMT2ASIRT2GSK3AGSK3B
SCHEMBL3362480 0.88 GSK3A (0.77) MEN1KMT2AMITFSIRT2GSK3A
SCHEMBL12990390 0.88 GSK3A (0.77) MEN1KMT2AMITFSIRT2GSK3A
SCHEMBL3362481 0.88 GSK3A (0.77) MEN1KMT2AMITFSIRT2GSK3A
SCHEMBL6392502 0.83 BRAF (0.64) MEN1KMT2ASIRT2GSK3AGSK3B
SCHEMBL10018549 0.82 KMT2A (0.74) MEN1KMT2AMITFSIRT2GFER
SCHEMBL10036665 0.82 KMT2A (0.74) MEN1KMT2AMITFSIRT2GFER
SCHEMBL12818321 0.81 AURKA (0.69) MEN1KMT2AMITFSIRT2GFER
SCHEMBL14426477 0.80 KMT2A (0.68) MEN1KMT2AMITFSIRT2POLB
SCHEMBL5164488 0.80 KMT2A (0.71) MEN1KMT2AMITFSIRT2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305121-A1 NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-12-02 US disclosed
US-20100305121-A1 NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-12-02 US disclosed
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305121-A1 NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE FADS2, ACOT7, FADS1 MEN1 3665/4885KMT2A 3767/4885MITF 2835/4885
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 MEN1 4004/4885KMT2A 4410/4885MITF 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.